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Abstract
Background:  In animal models, ischemia reperfusion (IR) injury triggers membrane lipid
degradation and accumulation of lipoxidative exacerbations in neurovascular unit, leading to blood
brain barrier (BBB) damage and neurologic deficits. In this study, we investigated whether impeding
membrane lipid breakdown by inhibiting secretory phospholipase A2 (sPLA2) activity reduces BBB
leakage, leading to neuroprotection and functional recovery.
Methods: Focal cerebral IR injury was induced by middle cerebral artery occlusion (MCAO) in
adult male rats. A sPLA2 inhibitor, 7,7-dimethyleicosadienoic acid (DEDA), was administered
following IR injury. DEDA-treated animals were compared with vehicle-treated in terms of BBB
leakage, edema, infarct volume, and neurological deficit. Membrane lipid degradation and the
expression/activity of sPLA2 were also assessed. The role of one of the sPLA2 products,
arachidonic acid (AA), on the morphology of the differentiated neuronal cell PC12 was examined
by light microscopy.
Results: Treatment with DEDA after IR injury not only reduced BBB leakage but also decreased
infarct volume and improved neurologic function. The treatment attenuated both the activity of
sPLA2 and the levels of sPLA2-derived oxidized products. The metabolites of lipid oxidation/
peroxidation, including the protein carbonyl, were reduced as well. The treatment also restored
the levels of glutathione, indicating attenuation of oxidative stress. In vitro treatment of PC12 cells
with DEDA did not restore the AA-mediated inhibition of neurite formation and the levels of
glutathione, indicating that effect of DEDA is up stream to AA release.
Conclusion: sPLA2-derived oxidative products contribute to significant neurovascular damage,
and treatment with sPLA2 inhibitor DEDA ameliorates secondary injury by reducing exacerbations
from lipoxidative stress.
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Background
Stroke involves a myriad of biochemical events [1]. Fol-
lowing cerebral ischemia-reperfusion (IR) injury, mem-
brane lipid degradation, reactive oxygen species (ROS)
generation, glutamate excitotxicity and calcium overload
are the major initial events that induce inflammation and
cellular death [2]. Excess release of calcium and glutamate
results in phospholipid hydrolysis and the release of ara-
chidonic acid (AA) via phospholipase activation [3].
Phospholipids are major lipid components crucial for
membrane integrity and synaptic function. Degraded lip-
ids compromise not only the structural integrity of the cel-
lular membrane but also produce reactive oxygen species
(ROS), overwhelming the antioxidant system in the neu-
rovascular unit [4].
ROS, generated through several cellular pathways follow-
ing IR, have been implicated in neuronal dysfunction [5].
Increased vulnerability of the brain to lipoxidative media-
tors following IR injury contributes to secondary injury
and impairment of brain functions [6]. Glutathione
(GSH), an endogenous antioxidant that reduces ROS lev-
els, plays a central role within the finely tuned network of
antioxidant systems that respond to insult. GSH responds
to oxidative stress through its peroxide scavenging func-
tions via glutathione S-transferase (GST) and glutathione
peroxidase (GPx) [2]. Accordingly, the GSH precursor N-
acetylcysteine (NAC) provided neurovascular protection
following IR injury [7], supporting the potential of reduc-
ing ROS strategy for stroke [6].
Understanding the effects of lipoxidative load on the
mechanisms of pro-inflammatory enzymes, like phos-
pholipases A2 (PLA2s), and their modulation for thera-
peutic purposes has gained significant recent attention
[8,9]. Among the different types of PLA2s, secretory PLA2s
(sPLA2s) play an important role in neuroinflammation
due to their non-specific nature to phospholipid substrate
[10,11]. Cytosolic PLA2 (cPLA2) will specifically release
AA; while sPLA2 does not have this specificity of fatty acid
too [12]. Due to their accessibility in the circulation and
in the tissues, sPLA2s activity leads to generation of several
potent mediators of inflammation. The products of
sPLA2, free fatty acids (FFA) including AA and lysophos-
phatidylcholine (LPC), are the most crucial bioactive lipid
metabolites. AA, which induces oxidative stress during its
metabolism, leads to either cell proliferation or apoptosis,
depending on the cell type in which it is metabolized [13-
16]. AA also regulates downstream signaling pathways of
p38 mitogen-activated protein kinase (MAPK) [17-19],
which is involved in the disruption of the blood brain bar-
rier (BBB) [20]. Furthermore, released free AA either acts
as a second messenger or it is further metabolized by rele-
vant enzymes to generate eicosanoid signaling molecules
like prostaglandins, leukotrienes and thromboxanes [21].
These, in turn, set the stage for oxidative and peroxidative
damage to cellular membranes [22,23].
Recent reports have shown that sPLA2s are active before
secretion from the cell [6] and can be re-internalized into
cells viacaveolae in which localized Ca2+ concentrations
may be sufficiently high to permit lipid turnover. Induc-
tion of sPLA2 triggers activation of cytosolic PLA2 (cPLA2)
via its receptor mediated internalization into the cytosol
and regulates the invasiveness of matrix metalloprotein-
ases (MMPs) [24]. MMPs have been reported to aggravate
IR injury through hemorrhagic transformation and BBB
disruption in the acute phase of stroke [25].
Membrane lipid degradation by sPLA2 and the conse-
quent lipoxidative metabolism have been documented as
crucial toxic mechanisms involved not only in IR injury
but also in other neurodegenerative diseases [8,26-28],
making these processes potential therapeutic targets for
neurovascular protection [29,30]. Increased expression of
sPLA2 has been reported in cerebral ischemia [12,31], and
sPLA2 inhibition provides protection against ischemic
injury [32,33]. Among different subtypes of sPLA2, group
IIA has been extensively studied [11,34], and inhibition of
this sPLA2 has been reported to reduce lesion volume fol-
lowing IR injury [9]. However, the role of sPLA2 and its
metabolic products in BBB disruption is not understood.
A selective inhibitor of sPLA2 IIA [35], 7,7-dimethylei-
cosadienoic acid (DEDA) is a non-toxic AA analog with
IC50 values in the range of 6–20 μM. DEDA has been doc-
umented to reduce sPLA2 activity significantly and
decrease carotid artery ischemia-evoked release of gluta-
mate and aspartate in the cerebral cortex when adminis-
tered after injury in rats [36]. Treatment with DEDA has
shown no effect on physiologic parameters, including
blood pressure, pH and blood gases [37]. However, it sig-
nificantly reduced levels of lipid metabolites including
LPC and 6-keto-PGF1 alpha [36]. Recently, we docu-
mented the therapeutic potential of DEDA against the
psychosine-mediated cellular toxicity implicated in the
pathology of Krabbe disease, a demyelinating neurode-
generative disease. Inhibition of sPLA2 by DEDA reduced
the levels of AA and LPC, resulting in the survival of oli-
godendrocytes after treatment with psychosine [38].
These studies indicate the potential of DEDA to reduce the
sPLA2-derived lipoxidative exacerbations so deleterious in
the neurovascular unit following IR injury.
Methods
Reagents and cell culture
Dulbecco's Modified Eagle's Medium (DMEM) with glu-
cose, L-glutamine and sodium pyruvate was purchased
from Mediatech, Inc. (Herndon, VA). Fetal Bovine Serum
(FBS) and Hank's balanced salt solution (HBSS) wereJournal of Neuroinflammation 2009, 6:21 http://www.jneuroinflammation.com/content/6/1/21
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obtained from Life Technologies (Carlsbad, CA). 2,3,5-
triphenyltetrazolium chloride (TTC), 3,4,5-dimethylthia-
zol-2-yl-2, 5-diphenyltetrazolium bromide (MTT) and 1-
chloro 2,4-dinitrobenzene (CDNB) were obtained from
Sigma-Aldrich Chemical Corporation (St. Louis, MO).
Antibodies against sPLA2-IIA and CD34+ were purchased
from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA).
DEDA was purchased from Biomol International L.P.
(Plymouth Meeting, PA, USA). 1-palmitoyl-2-[1-14C] ara-
chidonyl-sn-glycero-3-phosphocholine and – [1-14C] ara-
chidonic acid were obtained from American Radiolabeled
Inc., St. Louis, MO.
Experimental animals
All animal procedures were approved by the Medical Uni-
versity of South Carolina (MUSC)'s Animal Review Com-
mittee, and animals received humane care in compliance
with MUSC's experimental guidelines and the National
Research Council's criteria for humane care (Guide for the
Care and Use of Laboratory Animals).
Experimental design and administration of drugs
The animals were divided into four groups: (i) control
(sham-operated) group (ii) ischemia (60 minutes) and
reperfusion (24 hr) group (Vehicle or Veh), (iii) DEDA-
treated at reperfusion and repeated at 3 h of reperfusion
group (DEDA), and (iv) DEDA-treated at reperfusion
group. In the treatment group, DEDA (1 mg/kg body
weight) dissolved in sterile DMSO (25 μl) was slowly
infused via tail vein. Rats in the vehicle and sham groups
were administered the same volume of DMSO.
Focal cerebral ischemia
Male Sprague-Dawley rats weighing 250–300 g (Harlan
Laboratories, Wilmington, MA) were fasted overnight but
allowed access to water ad libitum. They were anesthetized
with an intramuscular injection of xylazine (10 mg/kg
body weight) and an intraperitoneal injection of keta-
mine hydrochloride (100 mg/kg). A rectal temperature
probe was introduced, and a heating pad was used to
maintain the body temperature at 37°C. Right middle cer-
ebral artery (MCA) was occluded as described by Longa et
al [39] with modifications [40,41]. Briefly, focal cerebral
ischemia was induced by introducing a 4 cm long silicone
coated (coating length 5 mm and 0.35–0.37 mm coating
diameter) specialized occluding suture for MCAO (Doc-
col Corporation, Redlands, CA; Cat# 4035 or 4037, as per
the weight of the animal) into the internal carotid artery
(ICA) via external carotid artery (ECA) stump until the
suture was wedged, and the tip occluded the proximal
stem of MCA, approximately internalizing 20 mm of total
length. 60 minutes post occlusion, the filament was with-
drawn to allow reperfusion and the ECA stump was
ligated and coagulated permanently. The animals were
euthanized by decapitation under deep anesthesia with a
pentobarbital overdose (150 mg/kg) at the specified time
period of reperfusion to harvest brain for biochemical
estimations or for immunohistochemical examination.
The brains were snap-frozen and stored at -70°C.
Measurement of physiologic parameters
The physiologic parameters were measured before 30 min
of MCAO and at 3.5 h after reperfusion (ie. 30 min after
DEDA treatment) and are presented in Table 1. Mean
blood pressure (MBP) and heart rate (HR) and blood pH
were measured without anesthesia. The rectal temperature
was monitored and maintained at about 37 to 37.8°C.
Body temperature was monitored by a probe maintained
at about 37 ± 0.5°C by a homeothermic blanket control
unit (Harvard Apparatus, Holliston, MA). Cranial temper-






Rectal Temp (°C) 37.0 ± 0.1 36.4 ± 0.2 37.8 ± 0.1 37.5 ± 0.1
Cranial Temp (°C) 37.2 ± 0.7 37.5 ± 0.8 37.8 ± 0.7 37.9 ± 0.9
MBP (mm Hg) 120.97 ± 3.93 121.1 ± 1.94 121.5 ± 4.0 129.1 ± 6.39
HR 355.5 ± 17.1 364.4 ± 21.39 362.3 ± 17.23 378.2 ± 8.67
pH 7.2 ± 0.2 7.4 ± 0.2 7.4 ± 0.3 7.4 ± 0.2
Measurements were performed before MCAO (base) and at 3.5 h after reperfusion without anesthesia as described in Methods. pH was measured 
in blood also at 3.5 h after reperfusion. Data are presented as mean ± SD for n = 3 in each group. Measurements were also performed for sham 
group. No significant differences were observed among the groups. Basal, 30 min before MCAO. HR, heart rate; MCAO, middle cerebral artery 
occlusion; MBP, mean blood pressure; Rep, reperfusion; Temp, temperatureJournal of Neuroinflammation 2009, 6:21 http://www.jneuroinflammation.com/content/6/1/21
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ature was measured by HSE Plugsys TAM-D (Harvard
Apparatus). Blood pH was measured by pH/blood gas
analyzer iSTAT (Heska, Fort Collins, CO). MBP and HR
were measured using a XBP1000 NIBP system (Kent Sci-
entific, Torrington, CT). It is non-invasive computerized
tail-cuff system and uses automated inflation/deflation
pump.
Evaluation of neurologic deficit
Neurologic deficits in the animals were assessed by an
observer blinded to the identity of the groups after 60 min
of ischemia and 24 h of reperfusion. The scoring was
based on the method of Huang et al. [42] and previously
adopted by us [43].
Measurement of ischemic infarct
Infarct volume was evaluated as described previously [44].
Briefly, after 24 h of reperfusion, the brain was quickly
removed, washed in ice-cold phosphate buffered saline
(PBS) and 2 mm coronal sections were obtained to incu-
bate with 2% TTC dissolved in saline for 20 min at 37°C.
After washing with chilled PBS for 5 min, images were
made and acquired in Photoshop 7.0 (Adobe Systems).
The infarct area was quantified using Scion image, an
image-analysis software program (Scion Corporation).
Quantitation of FFA, AA and LPC in the ipsilateral 
hemisphere of brain
Lipids were extracted from the ipsilateral hemisphere of
brain tissue by the Folch method as described earlier
[45,46]. FFA was determined and quantified using high
performance thin layer chromatography (HPTLC) plates
[46]. AA present in FFA was measured using capillary gas
chromatography (GC) as described by Rao and colleagues
[47]. Quantification of LPC was performed by one-
dimensional HPTLC (LHPK from Whatman, Inc.;
Florham Park, NJ) using the method described by Weer-
heim et al. [48], with modification. Briefly, plates were
developed in methyl acetate-1-propanol-chloroform-
methyl alcohol-0.25% KCl-acetic acid
(100:100:100:40:36.5:2; v/v/v/v/v/v) and visualized by
heating at 200°C for 6 min after spraying with 10%
CuSO4 in 8% phosphoric acid. Different concentrations
(0.2 to 5.0 mg) of LPC (1-palmitoyl LPC) were resolved
on the same plate as standard for quantification. LPC was
quantified by densitometric scanning using the Imaging
Densitometer (model GS-670; Bio-Rad).
Measurement of PLA2 Activity
PLA2 activity was measured as reported earlier [49]. Brain
tissue was homogenized in 10 mM HEPES buffer (pH 7.2)
containing 0.5 mM each of EGTA, EDTA and a 1× protease
inhibitor cocktail. The homogenate was centrifuged at 18,
000 × g, and the supernatants were collected. PLA2 activity
was determined as the release of [1-14C] arachidonic acid
from 1-palmitoyl-2-[1-14C] arachidonyl-sn-glycero-3-
phosphocholine.
cDNA synthesis and real time PCR for mRNA expression of 
sPLA2
cDNA synthesis and real time PCR analysis were carried
out as described earlier [50]. Total RNA from brain tissue
was isolated using Trizol reagent (Gibco BRL, Carlsbad,
CA) per manufacturer's instructions. Single-stranded
cDNA was synthesized from RNA samples of rat brains by
using the superscript preamplification system (Life Tech-
nologies, Carlsbad, CA). Quantitative real-time PCR was
performed with the Bio-Rad (Hercules, CA) iCycler iQ
Real-Time PCR Detection System per conditions
described previously [50]. Briefly, primer sets were
designed and obtained from Integrated DNA Technolo-
gies (IDT, Coralville, IA). The primer sequences were:
GAPDH, forward primer, 5'-CCTACCCCCAATG-
TATCGTTGTG-3', reverse primer, 5'-GGAGGAAT-
GGAGTTGCTGTTGAA-3'; sPLA2-IIA, forward primer, 5'-
GTGACTCATGACT GTTGTTAC-3', reverse primer, 5'-
CAAAACATTCAGCGGCAGC-3'. Thermal cycling condi-
tions were as follows: activation of iTaq DNA polymerase
at 95°C for 10 minutes, followed by 40 cycles of amplifi-
cation at 95°C for 30 seconds and 55–57.5°C for 1
minute. The normalized expression of the target gene with
respect to GAPDH was computed for all samples by using
Microsoft Excel data spreadsheets.
Immunohistochemistry
Protein expression of sPLA2 was detected by immunohis-
tochemical analysis. In brief, the brain tissue sections were
de-parafinized and re-hydrated in sequential gradations
of alcohol. After antigen unmasking in unmasking solu-
tion (Vector Labs, CA), sections were cooled and washed
three times for two minutes each in PBS. Sections were
immersed for 10 min in 3% hydrogen peroxide to elimi-
nate endogenous peroxidase activity and blocked in 1%
bovine serum albumin for 1 hr. Sections were incubated
overnight with a primary antibody (Santa Cruz Biotech-
nology, CA; 1:100 dilutions in blocking buffer). After
washing in PBS containing 0.1% Tween-20, sections were
incubated with a fluorophore tagged secondary antibody
(1:100 dilutions in blocking buffer) (Vector Labs, CA).
Fluorescence was visualized under the microscope. All the
sections were analyzed using a Zeiss Olympus Micro-
scope, and images were captured using a Kontron Digital
Camera. Different fields were recorded from different sec-
tions, and representative images were presented in figures.
Images were captured and processed in Adobe Photoshop
7.0 and were adjusted for brightness, contrast and
unmasking tools to enhance image clarity.
Measurement of protein carbonyl (PC) in brain tissue
Content of protein carbonyl was determined using the
method reported by Levine et al [51] with certain modifi-Journal of Neuroinflammation 2009, 6:21 http://www.jneuroinflammation.com/content/6/1/21
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cations. Tissue homogenates, prepared in chilled 20 mM
PBS (pH 7.4) containing 1× protease inhibitor cocktail,
were centrifuged at 2000 × g for 3–5 minutes to remove
debris. The supernatant was taken and incubated with
streptomycin sulfate (final concentration 1%) for 15 min
at room temperature, followed by centrifugation at 2800
× g for 5 min. 100 μl of supernatant was taken in dupli-
cates, and the protein was precipitated by adding 500 μL
of 20% chilled TCA. The mixture was centrifuged at 3000
× g, and the supernatant was discarded. The pellet was dis-
solved in 800 μL of 20 mM DNPH solution prepared in 2
M HCl, and incubated at room temperature in the dark for
1 hr with overtaxing every 15 min. Negative controls were
run in duplicates for each sample by adding 800 μL of 2
M HCL in place of DNPH solution. After one hr, 700 μl of
20% chilled TCA was added and kept on ice-bath for 5 –
10 minutes. The suspension was centrifuged at 10,000 × g
for 10 min, and the supernatant was discarded. The pellets
obtained were washed with 3 × 1 ml by ethanol – ethyl
acetate mixture (1:1). Finally, they were dissolved at 50°C
in 1 ml of 6 M guanidine hydrochloride solution prepared
in 0.1 M potassium phosphate buffer. The supernatant
was obtained by centrifugation at 10,000 × g. The yellow
colored complexes obtained were read vs. negative con-
trols at 370 nm to determine the amount of PC. The neg-
ative controls were read against 6 M-guanidine solution at
280 nm to determine protein concentrations.
Measurement of reduced glutathione (GSH) in brain tissue
Concentration of glutathione (GSH) was measured using
a colorimetric assay kit for glutathione from Oxis Research
(Portland, OR) as reported earlier [41]. Briefly, tissues
were minced and homogenized (20 ml/g tissue in 5%
metaphosphoric acid). Homogenates were centrifuged at
3,000 × g for 10 min. Supernatants were used to assay
GSH at 400 nm as described previously [41].
Evaluation of blood brain barrier (BBB) disruption by 
Evan's blue (EB) extravasation and measurement of 
edema
BBB leakage was assessed by the method of Weismann
and Stewart [52] with slight modification. The rats
received 100 μl of a 5% solution of EB in saline adminis-
tered intravenously after DEDA treatment. At the comple-
tion of reperfusion time, cardiac perfusion was performed
under deep anesthesia with 200 ml of saline to clear the
cerebral circulation of EB. The brain was removed, sliced
and photographed. The two hemispheres were isolated
and mechanically homogenized in 750 μl of N, N-
dimethylformamide (DMF). The suspension obtained
was kept at room temperature in the dark for 72 hr. It was
centrifuged at 10,000 × g for 25 minutes, and the superna-
tant was spectrofluorimetrically analyzed (λex 620 nm,
λem 680 nm).
At 24 h following MCAO, animals were euthanized to
determine brain water content (edema). The cortices,
excluding the cerebellum, were quickly removed and the
contralateral and the ipsilateral hemispheres separately
weighed. Each hemisphere was dried at 60°C for 72 hours
and the dry weight was determined. Water content was
calculated in ipsilateral hemisphere as: water content (%)
= (wet weight – dry weight)/wet weight × 100.
Maintenance of cell lines and study of morphological 
changes
PC12 pheochromocytoma cells (a neuronal cell line) were
purchased from ATCC (Manassas, VA, USA) and main-
tained in DMEM (4.5 g glucose/L) supplemented with
10% horse serum, 5% fetal bovine serum and 1% antibi-
otics. To investigate the effect of AA mediated morpholog-
ical changes on NGF-induced neuronal differentiation,
PC12 cells were initially cultured in the medium men-
tioned above under 5% CO2  in poly-D-lysine-coated
plates (Costar, Cambridge, MA). A medium containing
DMEM (4.5 g glucose/L), 0.1% bovine serum albumin
and 1% antibiotic was used in all differentiation studies.
Cells (x105/ml) were plated on 6-well polystyrene tissue
culture plates (Costar, Cambridge, MA) and grown for 4
days in serum containing medium. 20 ng/ml NGF was
added, which is the dose yielding 50% maximal differen-
tiation of PC12 cells. Neuronal differentiation was
observed after 72 hr by morphological parameters, specif-
ically the appearance of axodendritic processes > 40 μm
long (about 2–3 cell diameters), using phase contrast
microscopy. Under qualified differentiation conditions,
cells were labeled with 0.1 μCi of AA. The plates were pre-
treated with DEDA for 2 hr, followed by treatment with
cytokines and/or H2O2. Morphological and biochemical
alterations were assessed 24 hr later.
Statistical analysis
Statistical analysis was performed using software Graph-
pad Prism 3.0, unless otherwise stated. Values are
expressed as mean ± SD of n determinations or as men-
tioned. Comparisons among means of groups were made
with a two-tailed Student's t-test for unpaired variables.
Multiple comparisons were performed using one-way
ANOVA followed by the Bonferroni test. P-values < 0.05
were considered significantly different.
Results
DEDA improves neurological function and reduces infarct 
volume
The experimental animals were assessed for neurologic
deficit and infarctions at 24 hr of reperfusion following 60
min MCAO. Fig 1A–B shows that IR injury was reduced
significantly (p ≤ 0.01) in the DEDA treated at reperfusion
and repeated at 3 h of reperfusion group (infarct volumeJournal of Neuroinflammation 2009, 6:21 http://www.jneuroinflammation.com/content/6/1/21
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150 ± 20 mm3) compared to the Veh (infarct volume 365
± 40 mm3). The treatment with DEDA at reperfusion and
repeated at 3 h of reperfusion also improved neurologic
functions (Fig 1C). The neurologic score of individual ani-
mal from the Veh group was 4,3,3,3,2 (severe deficit) and
the animals in the treatment group (DEDA) had individ-
ual neurologic score 1,1,1,2,2 (mild deficit). We further
investigated the effectiveness of a single but equivalent
dose of DEDA administration at 0 h of reperfusion on inf-
arct volume and neurologic deficit. The single dose of
DEDA was found to be less effective at reducing infarct
volume than the repeated dose. However, reductions in
both the infarct volume (infarct volume 186 ± 25 mm3)
and neurologic deficit (median 2.0) in the single dose of
DEDA treated group were significantly improved as com-
pared to the Veh group. The selected dose of DEDA had no
significant effects on physiologic parameters (cranial tem-
perature, mean blood pressure, heart rate and pH) as
shown in Table 1.
DEDA reduces the levels of IR-mediated release of FFA and 
LPC
Increases in the levels of both neurovascular toxic FFA and
LPC have been documented following IR injury [29,33].
To test whether sPLA2 was responsible for altered lipid
metabolism, we treated the animals with DEDA at 0 and
3 hr of reperfusion following MCAO and measured the
levels of total FFA, including free AA and LPC after 24 hr
of reperfusion. The treatment significantly (p < 0.001)
reduced IR-mediated increased levels of total FFA (meas-
ured by HPTLC), free AA (measured by GC) and LPC
(measured by HPTLC) in the penumbra region of the ipsi-
lateral hemisphere (Fig 2A–C).
DEDA inhibits activity of Ca2+-dependent PLA2s and 
reduces sPLA2 enzyme expression but not sPLA2 mRNA 
expression
DEDA is reported as a specific and competitive inhibitor
of sPLA2 group II [35]. However, its effect on the expres-
sion of sPLA2 and the activity of other calcium-dependent
PLA2s is not clear. We investigated the effect of DEDA on
the expression of sPLA2. Fig 3A shows that DEDA inhib-
ited the activity of Ca2+-dependent PLA2s, which was sig-
nificantly increased (p < 0.01) in the ipsilateral side of
untreated animals compared to the contralateral. An RT-
PCR study showed that the treatment with DEDA did not
reduce mRNA expression measured at 4 hr after reper-
fusion following MCAO (Fig 3B). Enhanced expression of
the sPLA2 enzyme at the protein level was observed in the
penumbra region measured at 24 hr after reperfusion fol-
Post-injury treatment with DEDA protects the brain against  IR injury and improves neurologic score Figure 1
Post-injury treatment with DEDA protects the brain 
against IR injury and improves neurologic score. (A) 
Photographs showing the effect of DEDA (1 mg/kg) adminis-
tered at reperfusion and repeated at 3 h following reper-
fusion after 60 min MCAO on TTC-stained sections, (B) 
Effect of DEDA on infarct volume (measured in six serial 
coronal sections arranged from cranial to caudal regions) and 
(C) Effect of DEDA on neurologic score. Data for infarct vol-
ume (n = 5) are presented as means ± SD. Data for neuro-
logical deficit (n = 5) are presented as individual data points. 
** p < 0.01 vs. vehicle (Veh).
Effect of IR injury and DEDA treatment on the levels of FFA,  AA and LPC in brain tissue at 24 hours of reperfusion after  60 min MCAO Figure 2
Effect of IR injury and DEDA treatment on the levels 
of FFA, AA and LPC in brain tissue at 24 hours of 
reperfusion after 60 min MCAO. Levels of FFA (A) and 
AA (B) were measured using GC and content of LPC (C) 
was quantitated by HPTLC. Data are expressed as means ± 
SD from triplicate determinations of 5 different samples (n = 
5). Closed bars represent ipsilateral and open bars represent 
contralateral hemispheres. *** p < 0.001 vs. Sham, +++ p < 
0.001 vs. Veh and ++ p < 0.01 vs. Veh.Journal of Neuroinflammation 2009, 6:21 http://www.jneuroinflammation.com/content/6/1/21
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lowing MCAO using immunohistochemistry. However, it
was reduced in the DEDA-treated penumbral area (Fig
3C). DEDA is an activity inhibitor of sPLA2. However, the
mechanisms of DEDA's inhibition of enzyme expression
are not understood.
DEDA reduces levels of protein carbonyl and restores 
glutathione content
Increased protein carbonyl formation and decreased lev-
els of glutathione have been observed following IR injury
in animal models, mainly due to ROS formation [6,34].
However, the relationship between sPLA2 activity and the
imbalance of redox is not clear. To assess the effect of
DEDA on oxidative stress, we measured the levels of pro-
tein carbonyls and glutathione. The level of protein carb-
onyls was significantly increased (p < 0.05) in the
ipsilateral region from Veh animals compared to the
sham. However, a non-significant increase in the contral-
ateral side was also observed. The treatment with DEDA at
0 h and at 3 h of reperfusion significantly reduced protein
carbonyl formation (Fig 4A) indicating that DEDA
reduced oxidative burden following IR injury. Treatment
with DEDA under similar conditions increased the levels
of glutathione in the ipsilateral hemisphere (Fig 4B).
DEDA protects BBB integrity by reducing its leakage and 
decreasing edema
BBB disruption and edema are the hallmark of IR injury
leading to inflammation and secondary injury. An assess-
ment by the EB extravasation method showed reduced
BBB leakage after DEDA treatment (Fig 5A). Measurement
of fluorescence in the homogenized ipsilateral side indi-
cated a significant decrease in EB intensity in the DEDA-
treated groups compared to sham, indicating the efficacy
Effect of IR injury and DEDA on Ca2+ dependent PLA2 activ- ity, mRNA and protein expression of sPLA2 in brain tissue at  24 hours of reperfusion after 60 min MCAO Figure 3
Effect of IR injury and DEDA on Ca2+ dependent 
PLA2 activity, mRNA and protein expression of 
sPLA2 in brain tissue at 24 hours of reperfusion after 
60 min MCAO. IR induced activity of calcium-dependent 
PLA2 was measured in both ipsilateral as well as contralateral 
hemispheres. Treatment with DEDA reduced the PLA2 
activity (A). However, treatment with DEDA did not alter 
IR-induced mRNA expression of sPLA2 measured at 4 hours 
of reperfusion (B). Representative photomicrograph of pro-
tein expression of sPLA2 at 24 hour reperfusion (C). Data 
represented as means ± SD of triplicate determinations (n = 
5). * p < 0.05 vs. Sham, ** p < 0.01 vs. Veh-contra, +++ p < 
0.001 vs. Veh-Ipsi. Effect of IR and DEDA on levels of PC and GSH in brain tis- sue at 24 hours of reperfusion after 60 min MCAO Figure 4
Effect of IR and DEDA on levels of PC and GSH in 
brain tissue at 24 hours of reperfusion after 60 min 
MCAO. Levels of protein carbonyl were significantly ele-
vated in the ipsilateral from the Veh brain. Treatment with 
DEDA reduced the PC level (A). IR significantly depleted the 
level of GSH in the penumbra and treatment with DEDA 
attenuated the GSH content in the Veh brain (B). Data are 
expressed as means ± SD from triplicate determinations of 
four different samples in each group. *p < 0.05 vs. Sham, *** 
p < 0.001 and ** p < 0.01 vs. Sham, ++ p < 0.01 and + p < 
0.05 vs. Veh.Journal of Neuroinflammation 2009, 6:21 http://www.jneuroinflammation.com/content/6/1/21
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of DEDA for BBB protection. The results were further sup-
ported by decreased edema/water content in the ipsilat-
eral side of the DEDA treated animals as compared to the
vehicle treated group (Fig 5C).
DEDA inhibits the inflammation-mediated release of AA 
but does not protect against AA-induced morphological 
and oxidative alterations in neuronal cell lines
IR injury induces the expression of pro-inflammatory
cytokines, including TNF-α and IL-1β, leading to induc-
tion of sPLA2, generation of FFA/AA and accumulation of
ROS. FFA and especially unesterified AA are significant
mediators of oxidative stress, causing BBB disruption and
neuronal cell death [47]. Fig 6A shows the effects of H2O2
and TNF-α on the release of AA from PC12 cells. Treat-
ment with cytokine alone did not have a significant effect
on the release of free AA. However, H2O2 alone and in
combination with TNF-α significantly increased the
release of AA. A pre-treatment with DEDA inhibited the
release of AA remarkably. Fig 6B–C shows the effect of AA-
mediated alterations in cell morphology and oxidative
stress. A pre-treatment with DEDA failed to restore cell
morphology. Similarly, DEDA did not restore the AA-
mediated loss of GSH in these cells.
Discussion
In experimental stroke, BBB integrity is compromised
early and provides a therapeutic target of intervention
[53]. Studies have shown that modulation of PLA2 and/or
PLA2-derived products, including AA and LPC, has atten-
uated IR injury [11,47,54]. In this study, we tested the
hypothesis that DEDA, an sPLA2 inhibitor, attenuates IR
injury through modulation of BBB functions. The two
important forms of PLA2s, cPLA2 and sPLA2, are calcium
dependent and located in the cytosol. They cleave mem-
brane phospholipids at the sn-2 position to yield FFA/AA
and LPC. Earlier reports documented that IR injury acti-
vates these enzymes from a very early stage, continuing for
several days, mainly due to increased calcium overload,
which causes oxidative stress, inflammation and apopto-
sis [34,55,56]. Recent studies have shown the importance
of sPLA2 in IR injury since it has both a tissue localized
and a circulatory existence. Activation of sPLA2 leads to
enhanced release of free AA and accumulation of LPC, nei-
ther of which occurs under normal circumstances.
Released AA produces bioactive lipid mediators through
its lipoxidative metabolisms. AA-derived oxidative lipid
Effect of DEDA on IR injury-induced BBB leakage and edema Figure 5
Effect of DEDA on IR injury-induced BBB leakage 
and edema. Representative photographs showing extrava-
sation of Evan's blue (EB) in six coronal sections of brain (A). 
Spectrofluorimetric estimation of EB in six coronal sections 
(B). Significant EB leakage was observed in Veh brain and the 
leakage was reduced in the DEDA-treated group. EB extrava-
sation was not observed in Sham animals. Treatment with 
DEDA decreased the brain water content in ipsilateral brain 
(C). Closed bars represent ipsilateral and open bars repre-
sent contralateral hemispheres. Data are expressed as means 
± SD from triplicate determinations of three different sam-
ples in each group. *** p < 0.01 vs. Sham, ** p < 0.01 vs. Veh.
Effect of DEDA on release of AA, cell morphology and levels  of GSH in PC-12 cells Figure 6
Effect of DEDA on release of AA, cell morphology 
and levels of GSH in PC-12 cells. (A) Neuronal PC12 
cells were labeled with [14C] AA over night as described in 
Methods. Cells were treated with 20 μM of DEDA for 2 
hour followed by treatment with TNF-α (100 ng/ml) or/and 
H2O2 (20 μM). After 3 h, radioactivity released in the 
medium (100 μl) was measured. (B) Morphology of PC12 
cells after treatment with AA (50 μM) and DEDA (20 μM). 
(C) Effect of AA (100 μM) and DEDA (20 μM) on the GSH 
level. Data are expressed as means ± SD of (n = 3). * p < 
0.05 and ** p < 0.01 vs. control and ++ p < 0.01 and +p < 
0.05 vs. TNF-α+ H2O2 or H2O2.Journal of Neuroinflammation 2009, 6:21 http://www.jneuroinflammation.com/content/6/1/21
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metabolites and LPC cause BBB leakage, endothelial dys-
function and brain edema [10,57,58].
Under normal conditions, the PLA2 enzymes help to
maintain membrane composition and thus membrane
integrity. However, PLA2s produce excessive amount of
FFA/AA and LPC under pathological condition. A high
amount of accumulated LPC, as observed in IR injury (Fig
2C), may cause electrophysiological disturbances [59]
and hence membrane dysfunction. Post-ischemia treat-
ment with AA aggravates IR-induced BBB leakage and
water retention, enhancing oxidative stress through deple-
tion of GSH and increasing MDA levels [56]. IR is accom-
panied by generation of ROS/reactive nitrogen species
(RNS) and inflammation. Several reports show the bene-
ficial effects of anti-inflammatory therapy after IR injury.
Most are based on the inhibition of LOX and COX-2
enzymes, thus preventing the conversion of AA to prostag-
landins. However, studies on AA confirm that it has direct
deleterious effects itself during IR injury through other
mechanisms as well [14]. Therefore, inhibiting enhanced
AA/LPC release may be a more effective therapeutic strat-
egy over those that retard AA conversion to other inflam-
matory mediators. Elevated concentrations of FFA also
contribute to enhanced expression of monocytes and their
adhesion to endothelial cells [60], which may lead to BBB
leakage. In the present study, we observed the inhibitory
effect of DEDA on sPLA2 activity, which is responsible for
excessive FFA/AA and LPC release during IR injury.
In ischemic conditions, the initial injury in the core area
is caused mainly by necrotic neuronal cell death due to
the lack of oxygen and the depletion of energy. The cellu-
lar death during reperfusion is primarily apoptotic in
nature, which is also an energy dependent process. This
apoptosis expands the core injury, converting the penum-
bra previously amenable to therapeutic intervention into
a larger and permanently damaged infarct [41]. AA has
been reported to promote apoptotic cell death by enhanc-
ing caspase-3 and myeloperoxidase (MPO) activity [56].
On the other hand, accumulated LPC acts like a detergent
and helps to make the membrane more soluble [59]. The
BBB is a neurovascular system mainly composed of
endothelial and astroglial cells with a basal lamina. It is
highly discriminatory, and has selective permeability
inside the brain. These traits of the BBB suggest that the
combined effect of AA and LPC may be disruptive, and
disruption of BBB is one of the major causes of secondary
injury. In this disruption, unwanted cells, debris and
water transmigrate across and infiltrate the BBB, which
finally leads to vasogenic edema, a prominent cause of
mortality following IR injury.
Our findings show that DEDA significantly reduced the
infarct size and improved neurologic score (Fig 1A–C).
This effect may occur through inhibition of FFA/AA and
LPC release (Fig 2A–C). Fig 3A clearly indicates that, even
though DEDA down regulated PLA2 activity, it did not
have any significant effect on the expression of PLA2 at
mRNA levels (Fig 3B–C).
The mechanism of IR injury is complex and multi-facto-
rial. Among these factors is oxidative stress, which regu-
lates neuroinflammation [34,44]. An imbalance in the
oxidant-antioxidant homeostasis can be observed by stud-
ying GSH level. Fig 4A–B shows that IR injury resulted in
oxidative stress; excessive AA may be one of the major cul-
prits, as PLA2 is activated within minutes following stroke
in different cell type including reactive astrocytes [31]. On
one hand, AA weakens the endogenous antioxidant sys-
tem represented by GSH levels; on the other hand, it
enhances formation of lipid metabolites, which further
interact with various proteins, thus forming protein carb-
onyl. Carbonylation of proteins makes them inaccessible
to specific enzymes by altering their identity and hence
hindering their function and degradation. Supporting the
efficacy of DEDA, Fig 4A–B shows that treatment with
DEDA significantly attenuated the oxidative stress due to
IR injury. To further confirm the relationship between
excessive AA and oxidative stress, we studied an in vitro
model by treating the neuronal cells with H2O2 and AA.
Fig 6A shows that there is significantly increased AA
release, possibly resulting from activation of PLA2 due to
oxidative stress. DEDA significantly attenuated the altered
release of AA. Furthermore, Fig 6B–D shows that AA and
other lipid metabolites like 4-hydroxynonenal (4-HNE)
induced morphological changes and depleted GSH. GSH
plays significant role in stroke and its restoration by its
precursor NAC [7] or by CDP-choline [61] is associated
with neurovascular protection. These findings show that
the induction of oxidative stress occurs through lipid
metabolites, and this phenomenon helps to activate
PLA2, contributing to secondary injury. It also confirms
that DEDA may provide protection in IR injury by reduc-
ing oxidative stress through modulation of PLA2 activity
and excessive AA release. However, DEDA clearly does not
have direct antioxidant properties to combat oxidative
stress.
Earlier reports documented that AA leads to BBB dysfunc-
tion and edema [62,63]; it is possible that exogenously
accumulated LPC with a membrane-lytic activity may play
a synergistic role with AA. Fig 5A–B shows EB leakage
inside the brain as a marker of BBB disruption and dys-
function. This compromised BBB integrity leads to edema
due to an influx of water and other contents (Fig 5C).
Inhibition of PLA2 activity by DEDA in the acute phase
significantly reduced BBB leakage and edema formation.
BBB leakage and edema formation may have life-threaten-
ing consequences, worsening neurologic outcomes. Pres-Journal of Neuroinflammation 2009, 6:21 http://www.jneuroinflammation.com/content/6/1/21
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ervation of BBB integrity by DEDA treatment indicates
that the use of a PLA2 inhibitor in the acute phase of IR
injury may have favorable therapeutic outcomes.
Conclusion
The present study found that release of FFA/AA and LPC
are among the few critical earlier events of IR injury. Exces-
sive release of AA and LPC by sPLA2 leads to BBB dysfunc-
tion, inflammation and oxidative stress, which in turn,
cause secondary injury. Moreover, induction of sPLA2 and
the consequent accumulation of LPC and AA-metabolites
may compromise membrane integrity following IR injury.
Therefore, an inhibition of sPLA2 by DEDA or other phar-
macological means may protect BBB integrity and provide
significant therapeutic benefits following stroke.
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